U
RPTP

UBS’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

UBS’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$20K Buy
2,100
+800
+62% +$8.17K ﹤0.01% 8055
2014
Q2 		$15K Sell
1,300
-4,400
-77% -$40.1K ﹤0.01% 8498
2014
Q1 		$57K Buy
5,700
+5,100
+850% +$73.6K ﹤0.01% 6674
2013
Q4 		$8K Sell
600
-1,100
-65% -$15.1K ﹤0.01% 9284
2013
Q3 		$25K Buy
+1,700
New +$20.4K ﹤0.01% 7801

Other funds holding RPTP

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS's RPTP Position: Q3 2014 in Review

UBS reduced its RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) stake by 9.1% in Q3 2014, selling an estimated $1.53K and leaving 1,500 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #8504.

UBS first reported a position in RPTP in Q2 2013 and has held it in 6 quarters since. The position peaked at $111K in Q2 2013. 82 funds tracked by Wall St. Rank hold RPTP as of Q3 2014.

  • UBS held 1,500 shares of RAPTOR PHARMACEUTICAL CORP COM STK (DE) worth $14K as of Q3 2014.
  • UBS sold 150 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q3 2014, an estimated $1.53K.
  • RAPTOR PHARMACEUTICAL CORP COM STK (DE) made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8504 holding.
  • UBS first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and has held it in 6 quarters since.
  • UBS's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $111K in Q2 2013.
  • 82 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.